Background: The purpose of this study was to determine the risk of adverse cardiovascular events associated with use of calcium channel blocker (CCB) in hypertensive patients with acute myocardial infarction (AMI). Methods: A total of 16,265 acute myocardial infarction patients who were enrolled Korea Myocardial Infarction registry (KORMI) from February 2008 to March 2011. Among those patients, we analyzed 3,310 hypertensive patients with acute myocardial infarction who had 1-year follow-up after discharge. Patients were divided into two groups (CCB group; n=470, No CCB group; n=2840). The primary endpoint of cardiac death and non-cardiac death at 1-year follow up was retrospectively indexed. Results: Mean age was 66.74 짹 11.83 years and 2,069 (62.5%) were included in total population. There were no significant differences in baseline clinical characteristics. Blood pressures and ejection fraction (52.01 짹 11.40 % vs. 53.96 짹 12.23 %, p=0.003) at admission were higher in CCB group than non CCB group. Clopidogrel, beta-blocker and ACEi were more frequently used in non-CCB group. The use of ARB, nitroglycerin, and nicorandil were higher in CCB group. The incidence of twelve month death, including cardiac death and non-cardiac death, was not differences with regard to use of calcium channel blocker (4.1 % vs. 5.7%, p=0.068). After multivariate analysis, independent predictor of the primary endpoint was not the use of CCB but LV dysfunction (EF <45%). Conclusions: This study may support that the use of CCB was not harmful in hypertensive patients who had preserved systolic function. Key Words: Calcium channel blocker, Acute Myocardial Infarction